Developing effective treatments for ultra-rare diseases has long presented a profound paradox for the biopharmaceutical industry and regulatory bodies. While…
Read More
Terremoto Biosciences Secures $108 Million Series C to Advance Next-Generation AKT1 Inhibitors for Oncology and Rare Diseases
Terremoto Biosciences, a pioneering biotechnology company at the forefront of developing novel therapeutics targeting the PI3K/AKT pathway, announced today the…
Read More
Evogene, Systasy and LMU University Hospital Munich team up on AI-driven drug discovery for inflammatory diseases
An ambitious new international collaboration, bolstered by a prestigious pan-European EUREKA grant, is set to revolutionize the treatment landscape for…
Read More
Canada Invests C$79 Million in Aspect Biosystems to Accelerate Development of Bioengineered Cellular Medicines for Endocrine and Metabolic Diseases
Vancouver, BC – Aspect Biosystems, a pioneering company in the field of bioengineered cellular medicines, has received a significant C$79…
Read More
Microplastics Linked to Neurodegenerative Diseases Through Multiple Biological Pathways According to New International Study
Recent scientific investigations have unveiled a concerning correlation between the pervasive presence of microplastics in the environment and the rising…
Read More
Evogene, Systasy and LMU University Hospital Munich team up on AI-driven drug discovery for inflammatory diseases
A groundbreaking international collaboration, fortified by a prestigious pan-European EUREKA grant, has been officially launched to pioneer the development of…
Read More
Sanofi Secures Global Rights to Kali Therapeutics’ Promising Tri-Specific Antibody KT501 for Autoimmune Diseases in a Landmark $1.23 Billion Deal
Sanofi has entered into an exclusive global license agreement with Kali Therapeutics, a significant move that grants the pharmaceutical giant…
Read More
Gilead Sciences to Acquire Ouro Medicines for $2.2 Billion, Ushering in New Era of T-Cell Engagers in Autoimmune Diseases
Gilead Sciences is poised to make a significant entry into the burgeoning field of T-cell engagers (TCEs) with its $2.2…
Read More
Evogene, Systasy and LMU University Hospital Munich team up on AI-driven drug discovery for inflammatory diseases
A groundbreaking international collaboration, bolstered by a prestigious pan-European EUREKA grant, has been officially announced, aiming to pioneer the development…
Read More
Scientific Study Unveils Five Biological Pathways Linking Microplastics to Neurodegenerative Diseases Like Alzheimers and Parkinsons
The global proliferation of plastic pollution has moved beyond an environmental crisis into the realm of a significant public health…
Read More
